

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
Capitol Annex -Room 131**

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, November 15, 2012
1:00 P.M. to 4:30 P.M.

AGENDA

- I. Call to Order and Welcome
- II. Approval of Minutes: July 19, 2012 Meeting
- III. New Business
 - a. New Products to Market
 - i. Dymista[®]
 - ii. Sklice[™]
 - iii. Neupro[®]
 - iv. Viokace[™]
 - v. Pertzye[™]
 - vi. Myrbetriq[™]
 - vii. Tudorza[™] Pressair[™]
 - viii. Xtandi[®]
 - ix. Bosulif[®]
 - b. Clinical Criteria Reviews
 - i. Truvada[®] Clinical Criteria
 - ii. Nucynta[®] ER Clinical Criteria
 - c. Existing Class Reviews
 - i. First-Generation Antipsychotics
 - ii. Second-Generation Antipsychotics
 - iii. Second-Generation Antipsychotics Clinical Criteria
 - iv. Injectable Antipsychotics
 - v. Injectable Antipsychotics Clinical Criteria
 - vi. Second-Generation Antipsychotic and SSRI Combinations
 - vii. Second-Generation Antipsychotics and SSRI Combinations Clinical Criteria
 - viii. First Generation Anticonvulsants
 - ix. Second Generation Anticonvulsants
 - x. Banzel[™] Clinical Criteria
 - xi. Lyrica[®] Clinical Criteria
 - xii. Sabril[®] Clinical Criteria
 - xiii. Anticonvulsants, Carbamazepine Derivatives
 - xiv. Stimulants and Related Agents
 - xv. Stimulants and Related Agents Clinical Criteria
 - xvi. Strattera[®] Clinical Criteria

- xvii. Provigil[®]/Nuvigil[®] Clinical Criteria
- xviii. SSRIs
- xix. SNRIs
- xx. Cymbalta[®] Clinical Criteria
- xxi. New Generation Antidepressants
- xxii. Tricyclic Antidepressants
- d. New Class Reviews
 - i. MAOIs
- IV. Adjournment
 - a. Next Meeting
 - i. January 17, 2013
 - ii. March 21, 2013
 - b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session please complete the Speaker Request Form posted on the Kentucky and Magellan Medicaid Administration websites.